Repligen Company Profile - Aug 04, 2011

Document Sample
Repligen  Company Profile - Aug 04, 2011 Powered By Docstoc
					Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Repligen Corporation
                                                                                        440 Wheelers Farms Road
                                                                                        Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:DBNN                                Key Data

   Repligen Corporation (Repligen) is a biopharmaceutical company focused on the           Ticker:
   development and commercialization of therapies that harness biological pathways         RGEN
   and deliver value to patients and clinicians in neurology, gastroenterology and
   orphan diseases. As of March 31, 2010, the Company was conducting a number of           2011 Sales:
   drug development programs for diseases, such as pancreatitis, bipolar disorder,
                                                                                           26,558,024
   Friedreich's ataxia and spinal muscular atrophy. It also has a bioprocessing business
   that focuses on the development and commercialization of products that are used
   for the production of biopharmaceuticals. Repligen sells a line of commercial           Major Industry:
   bioprocessing products based on Protein A, as well as single or limited campaign use    Drugs, Cosmetics & Health
   pre-packed chromatography columns, which are used in the production of                  Care
   monoclonal antibodies and other biopharmaceutical manufacturing applications. In
   March 2010, the Company announced that it acquired the assets of BioFlash               Sub Industry:
   Partners, LLC, (BioFlash).                                                              Ethical Drug Manufacturers
                       Stock Chart                                   Officers
                                                                    Chairman               Country:
                                                                Dr. Alexander Rich         United States

                                                                 Joint Chairman            Currency:
                                                                 Karen A. Dawes
                                                                                           U.S. Dollars

                                                         President & Chief Executive
                                                                                     Fiscal Year Ends:
                                                             Dr. Walter C. Herlihy
                                                                                     March
                                                              Chief Financial Officer
                                                                  William J. Kelly         Employees
                                                                                           66

                                                                                           Exchanges:
                                                                                           NAS

                                                                                           Share Type:
                                                                                  
				
DOCUMENT INFO
Description: Repligen Corporation (Repligen) is a biopharmaceutical company focused on the development and commercialization of therapies that harness biological pathways and deliver value to patients and clinicians in the fields of neurology and gastroenterology. As of March 31, 2010, Repligen was conducting a number of drug development programs for diseases, such as pancreatitis, Friedreich's ataxia and spinal muscular atrophy. The Company also has a bioprocessing business that focuses on the development and commercialization of products that are used in the production of biopharmaceuticals. As of March 31, 2011, the Company sold a range of commercial bioprocessing products based on Protein A, as well as a line of pre-packed chromatography columns, which are used in the production of monoclonal antibodies and other biopharmaceutical products.
BUY THIS DOCUMENT NOW PRICE: $24.95 100% MONEY BACK GUARANTEED
PARTNER Wright Investors' Service
Wright Investors' Service is an internationally recognized investment management and financial advisory firm headquartered in Milford, Connecticut. For more than 40 years, Wright has used well-defined and sophisticated investment strategies to help institutions, plan sponsors, bank trust departments, trust companies and individual investors achieve their financial objectives through a sensible approach to managing assets that balances risk and return.